Big Readouts For AstraZeneca, Daiichi Sankyo And Gilead At Lung Cancer Congress

Data At WCLC From Tagrisso And A Host Of ADCs

AstraZeneca’s Tagrisso could consolidate its place in EGFR-positive lung cancer, while Daiichi looks to go it alone with its own antibody-drug conjugate.

Suntec Singapore — Suntec Convention Centre in Singapore plays host to this year's WCLC congress. • Source: Shutterstock

The upcoming World Conference on Lung Cancer, being held in Singapore from 9-12 September, has a number of major readouts in targeted lung cancer therapy and antibody drug conjugates (ADCs) including presentations from AstraZeneca, Daiichi Sankyo and Gilead.

The meeting is particularly important for AstraZeneca, which is looking to extend its dominance in non-small cell lung cancer (NSCLC) with new data from its EGFR-targeting small-molecule blockbuster Tagrisso (osimertinib) and for its Daiichi Sankyo-partnered ADCs,

Big Readouts For AstraZeneca, Daiichi Sankyo And Gilead At Lung Cancer Congress

Data At WCLC From Tagrisso And A Host Of ADCs

More from Anticancer

More from Therapy Areas